SMFM

SMFM 2025: Higher aspirin dose doesn’t reduce preeclampsia risk

February 5, 2025

An increased aspirin dose doesn’t significantly reduce the incidence of preeclampsia in high-risk pregnancies. The findings, presented at the Society for Maternal-Fetal Medicine annual meeting, suggest that a lower dose is sufficient for preeclampsia prevention and could potentially minimize medication-related risks.

Study details: The Low Doses of Aspirin in the Prevention of Preeclampsia (ASAPP; NCT04070573) trial compared the efficacy of 162 mg vs. 81 mg aspirin daily in preventing preeclampsia in high-risk pregnancies. Participants (n = 400) were randomized at <16 weeks of gestation and monitored throughout pregnancy and postpartum. The primary outcome was the incidence of preterm preeclampsia or preeclampsia with severe features.

Results: Of the 369 participants included in the intention-to-treat analysis, the incidence of preterm preeclampsia or preeclampsia with severe features was similar between the 162-mg group (13%) and the 81-mg group (14%) (p = 0.7). Preliminary findings suggest the higher aspirin dose showed statistical, but not clinical, significance in reducing preeclampsia risk among patients with multifetal gestations (odds ratio, 0.2; 95% confidence interval, 0.0-0.9).

Source:

Khander, A. et al. (2025, February 1). Comparing 162mg vs. 81mg Aspirin for Prevention of Preeclampsia (ASAPP): A Randomized Control Trial. Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting – LB06. Retrieved from https://smfm2025.eventscribe.net/agenda.asp?startdate=2/1/2025